ClinicalTrials.gg
RecruitingNCT07324278Updated Aug 25, 2026

Hybrid Stroke Rehab With Mirror Priming

An interventional study of Mirror priming and Conventional therapy in Cardiovascular Diseases, Stroke and Cerebrovascular Disorders, sponsored by I-Shou University. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Primary conditionStrokeRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stroke
Why
  1. The study's listed conditions name Stroke, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by I-Shou University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 394 studies in Stroke with a site in Taiwan — 73 open to participants now, 82 under way, 4 of them phase 3. Stroke · Taiwan.

Planned enrollment
112th of 337
81 · median 54
Started
2026
with 8 others
No phase
261 of 394
63 open now
Primary completion
2030-09
later than 80 of 81 live
Registered
375th of 394
by date

Among the 394 studies in Stroke with a site in Taiwan, this one is the 112th largest by planned enrollment of the 337 interventional ones that give a count, is one of 9 that started in 2026, is one of 261 with no phase, reaches primary completion later than 80 of the 81 other live ones, and was the 375th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

73 of the 394 studies in Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.

03

Conditions studied

  • Cardiovascular Diseases
  • Stroke
  • Cerebrovascular Disorders

Browse trials for

Keywords

  • Rehabilitation
  • Mirror Therapy
04

In context

Stroke Reclassified

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

This study's planned enrollment of 81 is above the median of 48 across 6,049 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

I-Shou University is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Compared within Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A first-ever unilateral stroke ≥3 months
  2. Age between 20 and 80 years
  3. Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
  4. No severe spasticity in any joints of the affected arm
  5. Ability to follow the instructions
  6. No participation in other studies during the study period
  7. Willingness to provide informed written consent.

Exclusion criteria

Exclusion Criteria:

  1. Serious medical problems or poor physical conditions that might be detrimental to study participation.
  2. Received or planned botulinum toxin injections within 3 months prior to or during the trial
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    High-dose enhanced mirror priming group

    Behavioral: Mirror priming · Behavioral: Conventional therapy

  • Experimental
    Low-dose enhanced mirror priming group

    Behavioral: Mirror priming · Behavioral: Conventional therapy

  • Active comparator
    Active control group

    Behavioral: Conventional therapy

Interventions

  • BehavioralMirror priming

    During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.

  • BehavioralConventional therapy

    Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.

07

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment

    Time frame: Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.

Secondary outcomes

  1. Grip and pinch power

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  2. Revised Nottingham Sensory Assessment

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  3. Berg Balance Scale

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  4. Motor Activity Log

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  5. ABILHAND Questionnaire

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  6. Chedoke Arm and Hand Activity Inventory

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  7. Stroke Impact Scale

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

  8. Stroke Self-Efficacy Questionnaire

    Time frame: Baseline, 4 weeks, and 3 months post-intervention.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2030, 55 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 55 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 7, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Sep 30, 2030
CompletionEst.
Dec 31, 2030
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07324278
Lead sponsor
I-Shou University
Responsible party
Yi-chun Li (Principal Investigator, I-Shou University) — Principal investigator
First posted
Jan 7, 2026
Start date
Feb 2, 2026
Primary completion
Sep 30, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 25, 2026

Study contacts

Yi-chun Li, PhD
Contact
joyjoyfish@gmail.com
+886-7-6151100 ext. 7514

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion